Table 3.
Viability (A) and mortality (B) of the A. aegypti individual treatment with burchellin
| A |
L3-L4 |
L4 - Pupae |
Pupae -adult |
L3-Adult |
||||
|---|---|---|---|---|---|---|---|---|
| X ± SD | % | X ± SD | % | X ± SD | % | X ± SD | % | |
| Control |
10.0 ± 0 |
100 |
10.0 ± 0 a |
100 |
10.0 ± 0a |
100 |
10.0 ± 0a |
100 |
| Control 2 |
10.0 ± 0 |
100 |
10.0 ± 0 ab |
100 |
10.0 ± 0ab |
100 |
10.0 ± 0ab |
100 |
| 0.5 μg/mL |
10.0 ± 0 |
87 |
8.7 ± 0.6 ab |
35 |
3.0 ± 1.0 c*** |
100 |
3.0 ± 1.0 c*** |
30 |
| 1 μg/mL |
10.0 ± 0 |
87 |
8.7 ± 0.6 ab |
42 |
3.7 ± 2.0 c*** |
64 |
2.3 ± 1.2 c*** |
27 |
| 3.8 μg/mL |
10.0 ± 0 |
90 |
9.0 ± 1.7 ab |
22 |
2.0 ± 2.0 c*** |
67 |
1.3 ± 1.5 c*** |
15 |
| 5 μg/mL |
10.0 ± 0 |
87 |
8.3 ± 1.2 ab |
12 |
1.0 ± 1.0 c*** |
67 |
0.7 ± 0.6 c*** |
8 |
| 10 μg/mL |
10.0 ± 0 |
27 |
2.7 ± 1.2 c*** |
38 |
1.0 ± 1.0c*** |
67 |
0.7 ± 0.6 c*** |
7 |
| 30 μg/mL |
10.0 ± 0 |
20 |
2.0 ± 0 c*** |
0 |
0 |
0 |
0 |
0 |
|
B |
Larvae |
Pupae |
||||||
|
X ± SD |
VI |
% |
X ± SD |
VI |
% |
|||
| Control |
0 |
0 |
0 |
0 |
0 |
0 |
||
| Control 2 |
0 |
0 |
0 |
0 |
0 |
0 |
||
| 0.5 μg/mL |
7 ± 1 c*** |
3-38 |
70 |
0 |
0 |
0 |
||
| 1 μg/mL |
7 ± 0c*** |
2-31 |
63 |
0 |
0 |
0 |
||
| 3.8 μg/mL |
8 ± 2 cd*** |
2-36 |
80 |
0.7 ± 1.2 |
22-22c |
33 |
||
| 5 μg/mL |
9 ± 0 cd*** |
2-39 |
90 |
0.3 ± 0.6 |
18-18c |
33 |
||
| 10 μg/mL |
9 ± 1 cd*** |
2-30 |
90 |
0.3 ± 0.6 |
28-28c |
33 |
||
| 30 μg/mL | 10 ± 0 cd*** | 2-4 | 100 | 0 | 0 | 0 | ||
Burchellin individual treatment on A. aegypti at 0.5 - 30 μg/mL concentration. Values are mean ± standard deviation (X ± SD), average of three replicates of 10 larvae L3 per each group. Values followed by the same letter did not significantly different from each other, P > 0.05 when the Tukey test was used. Significance levels are represented as ***P < 0.001 vs. Control 2 = Acetone control.